HAVRIX 720 JUNIOR 720 UNIT / 0.5 ML
HEPATITIS A VIRUS, INACTIVATED : 720 UNIT / 0.5 ML · DIN 02231056 · GLAXOSMITHKLINE INC
Health Canada status: MARKETED
What is HAVRIX 720 JUNIOR?
HAVRIX 720 JUNIOR 720 UNIT / 0.5 ML contains HEPATITIS A VIRUS, INACTIVATED : 720 UNIT / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02231056, held by GLAXOSMITHKLINE INC, supplied as SUSPENSION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 22-Aug-2002. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02231056 |
|---|---|
| Brand name | HAVRIX 720 JUNIOR |
| Generic / active ingredient | HEPATITIS A VIRUS, INACTIVATED : 720 UNIT / 0.5 ML |
| Manufacturer | GLAXOSMITHKLINE INC |
| Strength | 720 UNIT / 0.5 ML |
| Dosage form | SUSPENSION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Schedule D |
| ATC code | J07BC02 HEPATITIS A, INACTIVATED, WHOLE VIRUS |
| AHFS class | 80:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-Aug-2002 |
| Original market date | 1997-09-23 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code J07BC02 HEPATITIS A, INACTIVATED, WHOLE VIRUS. 4 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AVAXIM | 160 UNIT / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | DIN 02237792 |
| HAVRIX 1440 | 1440 UNIT | SUSPENSION | GLAXOSMITHKLINE INC | MARKETED | DIN 02187078 |
| VAQTA | 50 UNIT | SUSPENSION | MERCK CANADA INC | MARKETED | DIN 02229702 |
| AVAXIM - PEDIATRIC | 80 UNIT / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | CANCELLED POST MARKET | DIN 02243741 |
| AVAXIM - PEDIATRIC -(5ML VIAL) | 800 UNIT / 5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | CANCELLED PRE MARKET | DIN 02243750 |
| EPAXAL | 500 UNIT / 0.5 ML | LIQUID | BERNA BIOTECH LTD | CANCELLED POST MARKET | DIN 02239910 |
| HAVRIX - 720UNIT/ML SUS | 720 UNIT | SUSPENSION | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02108216 |
Who else supplies HEPATITIS A, INACTIVATED, WHOLE VIRUS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. HEPATITIS A, INACTIVATED, WHOLE VIRUS appears in 66 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.